Conexxence® (denosumab-bnht) – New biosimilar approval

- On March 25, 2025, Fresenius Kabi announced the FDA approval of Conexxence (denosumab-bnht), biosimilar to Amgen's Prolia® (denosumab).
    - Conexxence is the fourth FDA-approved biosimilar to Prolia.
    - Sandoz's Jubbonti® (denosumab-bbdz), Samsung Bioepis' Ospomyv™ (denosumab-dssb) and Celltrion's Stoboclo® (denosumab-bmwo) were previously approved as biosimilars to Prolia.
- Conexxence, Stoboclo, Ospomyv, Jubbonti and Prolia share the following indications:
    - Treatment of postmenopausal women with osteoporosis at high risk for fracture
    - Treatment to increase bone mass in men with osteoporosis at high risk for fracture
    - Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
    - Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
    - Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
- The approval of Conexxence is based on review of a comprehensive data package and totality of evidence demonstrating a high degree of similarity to its reference product, Prolia.
- Like Prolia, Conexxence carries a boxed warning for severe hypocalcemia in patients with advanced kidney disease.
- Conexxence is contraindicated in patients with:
    - Hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating therapy with Conexxence.
    - Pregnancy: Denosumab products may cause fetal harm when administered to a pregnant woman.
    - Hypersensitivity: Reactions have included anaphylaxis, facial swelling, and urticaria.
- Warnings and precautions for Conexxence include severe hypocalcemia and mineral metabolism changes; drug products with same active ingredient; hypersensitivity; osteonecrosis of the jaw; atypical subtrochanteric and diaphyseal femoral fractures; multiple vertebral fractures following discontinuation of treatment; serious infections; dermatologic adverse reactions; musculoskeletal pain; suppression of bone turnover; and hypercalcemia in pediatric patients with osteogenesis imperfecta.
- The most common adverse reactions (> 5% and more common than placebo) with Conexxence use in postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.
- The most common adverse reactions (> 5% and more common than placebo) with Conexxence use in male osteoporosis were back pain, arthralgia, and nasopharyngitis.

Continued . . .

- The most common adverse reactions (> 3% and more common than active-control group) with Conexxence use in glucocorticoid-induced osteoporosis were back pain, hypertension, bronchitis, and headache.

- The most common adverse reactions (> 5% and more common than placebo) with Conexxence use in male osteoporosis were back pain, arthralgia, and nasopharyngitis.

- The most common adverse reactions (≥ 10% and more common than placebo) with Conexxence use in patients with bone loss due to hormone ablation for cancer were arthralgia and back pain.

- The recommended dosage of Conexxence is 60 mg administered as a single subcutaneous injection once every 6 months.

    — Conexxence should be administered by a healthcare professional.
    — All patients should receive calcium 1,000 mg daily and at least 400 IU vitamin D daily.

- Fresenius Kabi's launch plans for Conexxence are pending. Conexxence will be available as a 60 mg/mL solution in a single-dose prefilled syringe.

    — A confidential settlement agreement signed between Amgen and Fresenius Kabi allows for launch of Conexxence in mid-2025.

Optum